6-Mar-2026
Baron Health Care Fund adds TMO, ARQT, and ELAN; exits Cidara Therapeutics MASI among Q4 moves
Seeking Alpha News (Fri, 6-Mar 8:28 AM ET)
Baron Health Care Fund adds TMO, ARQT, and ELAN; exits Cidara Therapeutics, MASI among Q4 moves
Seeking Alpha News (Fri, 6-Mar 8:28 AM ET)
Repligen Corporation to Present at Upcoming March Conferences
Globe Newswire (Thu, 5-Mar 7:30 AM ET)
Globe Newswire (Tue, 24-Feb 7:30 AM ET)
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Tue, 10-Feb 7:30 AM ET)
Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
Globe Newswire (Tue, 6-Jan 7:30 AM ET)
Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
Globe Newswire (Thu, 18-Dec 7:30 AM ET)
Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows
Globe Newswire (Tue, 16-Dec 7:30 AM ET)
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Repligen trades on the NASDAQ stock market under the symbol RGEN.
As of March 6, 2026, RGEN stock price declined to $119.99 with 697,809 million shares trading.
RGEN has a beta of 1.45, meaning it tends to be more sensitive to market movements. RGEN has a correlation of 0.26 to the broad based SPY ETF.
RGEN has a market cap of $6.75 billion. This is considered a Mid Cap stock.
Last quarter Repligen reported $198 million in Revenue and $.49 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.05.
In the last 3 years, RGEN traded as high as $211.13 and as low as $102.97.
The top ETF exchange traded funds that RGEN belongs to (by Net Assets): VTI, IJH, VB, VBK, VXF.
RGEN has underperformed the market in the last year with a price return of -25.1% while the SPY ETF gained +18.7%. RGEN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -27.3% and -11.6%, respectively, while the SPY returned -1.7% and -2.5%, respectively.
RGEN support price is $120.99 and resistance is $129.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGEN shares will trade within this expected range on the day.